Chlamydia Infections - Pipeline Review, H1 2018

  • ID: 4479926
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abera Bioscience AB
  • Evofem Biosciences Inc
  • Merck & Co Inc
  • Prokarium Ltd
  • SATT IDF Innov SAS
  • SIGA Technologies Inc
  • MORE
Chlamydia Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H1 2018, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abera Bioscience AB
  • Evofem Biosciences Inc
  • Merck & Co Inc
  • Prokarium Ltd
  • SATT IDF Innov SAS
  • SIGA Technologies Inc
  • MORE
Introduction

Report Coverage

Chlamydia Infections - Overview

Chlamydia Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chlamydia Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chlamydia Infections - Companies Involved in Therapeutics Development

Abera Bioscience AB

Abivax SA

Evofem Biosciences Inc

Genetic Immunity Inc

Lead Discovery Center GmbH

Merck & Co Inc

NanoBio Corp

Prokarium Ltd

QureTech Bio AB

SATT IDF Innov SAS

Selecta Biosciences Inc

SIGA Technologies Inc

Vault Pharma Inc

Vaxine Pty Ltd

Chlamydia Infections - Drug Profiles

Ab-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ChlamyDerm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia trachomatis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia trachomatis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-669 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia Infections - Dormant Projects

Chlamydia Infections - Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: New weapon in fight against antibiotic resistance discovered

Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice

Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology

Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chlamydia Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2018

Chlamydia Infections - Pipeline by Abivax SA, H1 2018

Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H1 2018

Chlamydia Infections - Pipeline by Genetic Immunity Inc, H1 2018

Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H1 2018

Chlamydia Infections - Pipeline by Merck & Co Inc, H1 2018

Chlamydia Infections - Pipeline by NanoBio Corp, H1 2018

Chlamydia Infections - Pipeline by Prokarium Ltd, H1 2018

Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2018

Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H1 2018

Chlamydia Infections - Pipeline by Selecta Biosciences Inc, H1 2018

Chlamydia Infections - Pipeline by SIGA Technologies Inc, H1 2018

Chlamydia Infections - Pipeline by Vault Pharma Inc, H1 2018

Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H1 2018

Chlamydia Infections - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Chlamydia Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abera Bioscience AB
  • Abivax SA
  • Evofem Biosciences Inc
  • Genetic Immunity Inc
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • NanoBio Corp
  • Prokarium Ltd
  • QureTech Bio AB
  • SATT IDF Innov SAS
  • Selecta Biosciences Inc
  • SIGA Technologies Inc
  • Vault Pharma Inc
  • Vaxine Pty Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll